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ABSTRACT 
A leading hypothesis for schizophrenia and related psychotic disorders proposes that cortical brain 
disruption leads to subcortical dopaminergic dysfunction, which underlies psychosis in the majority of 
patients who respond to treatment. Although supported by preclinical findings that prefrontal cortical 
lesions lead to striatal dopamine dysregulation, the relationship between prefrontal structural volume 
and striatal dopamine function has not been tested in people with psychosis. We therefore 
investigated the in vivo relationship between striatal dopamine synthesis capacity and prefrontal grey 
matter volume in treatment responsive patients with psychosis, and compared them to treatment non-
responsive patients, where dopaminergic mechanisms are not thought to be central. 40 patients with 
psychosis across two independent cohorts underwent 18F-DOPA PET scans to measure dopamine 
synthesis capacity (indexed as the influx rate constant Kicer) and structural 3T MRI. The PET, but not MR, 
data have been reported previously. Structural images were processed using DARTEL-VBM. GLM 
analyses were performed in SPM12 to test the relationship between prefrontal grey matter volume 
and striatal Kicer. Treatment responders showed a negative correlation between prefrontal grey matter 
and striatal dopamine synthesis capacity, but this was not evident in treatment non-responders. 
Specifically, we found an interaction between treatment response, whole striatal dopamine synthesis 
capacity and grey matter volume in left (pFWE corr.= 0.017) and right (pFWE corr.= 0.042) prefrontal 
cortex. We replicated the finding in right prefrontal cortex in the independent sample (pFWE corr.= 
0.031). The summary effect size was 0.82. Our findings are consistent with the long-standing 
hypothesis of dysregulation of the striatal dopaminergic system being related to prefrontal cortex 
pathology in schizophrenia, but critically also extend the hypothesis to indicate it can be applied to 
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treatment-responsive schizophrenia only. This suggests that different mechanisms underlie the 
pathophysiology of treatment-responsive and treatment-resistant schizophrenia. 
 
 
Key words: schizophrenia, treatment response, neurobiology, antipsychotics, imaging, resistant, 
biomarker, neurochemistry 
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INTRODUCTION 
Schizophrenia is a severe mental illness, affecting approximately 1% of the population1 and ranks as a 
leading cause of disability and functional impairment.2 Disability is compounded by the fact that 
approximately one third of patients with schizophrenia show limited or no response to first-line 
antipsychotic drugs.3-6 It has recently been suggested that there may be two different subtypes of 
schizophrenia (hyperdopaminergic and normodopaminergic) with differing neurobiological 
mechanisms.7, 8 Investigating the pathophysiology of schizophrenia is essential for screening, early 
intervention, secondary prevention and treatment of this illness. 
One focus of research exploring the neurobiology of schizophrenia has been the interaction between 
prefrontal cortex (PFC) and striatal function. Two of the most robust neuroimaging alterations in 
schizophrenia are increased striatal dopamine synthesis and release capacity9, and reduced grey 
matter volume in the prefrontal cortex.10-15 Preclinical studies have provided evidence for a key role of 
PFC in regulating dopaminergic neuronal firing and striatal dopamine release: PFC lesions in rats have 
been linked to increased striatal dopamine levels16, 17 and to increased release of subcortical dopamine 
evoked by drug challenges or stress18-20. These findings have led to the hypothesis that increased 
striatal dopaminergic transmission in schizophrenia may be a consequence of a primary prefrontal 
alteration.16, 21-24 
Recent human studies showed an inverse correlation between frontal cortical thickness and d-
amphetamine-induced striatal dopamine response in healthy subjects.25, 26 Moreover, correlations 
between striatal dopaminergic function and prefrontal functional activation during cognitive tasks have 
been reported both in individuals at clinical high risk for psychosis27 and in patients with 
 5
schizophrenia.28 Furthermore, a correlation was demonstrated between reduced N-acetyl-aspartate, a 
measure of neuronal integrity, in the PFC and increased amphetamine-induced dopamine release in 
patients with schizophrenia.29 The most clear-cut elevation in dopamine synthesis and release capacity 
has been found in the part of the striatum that receives projections from prefrontal cortical regions, 
termed the associative striatum30-34 and confirmed by meta-analysis35, further suggesting a link 
between prefrontal cortex and striatum in schizophrenia. However, it is not known if reduced PFC 
volume is associated with elevated striatal dopaminergic function in vivo in patients with 
schizophrenia, as suggested by the preclinical studies reviewed above. 
We therefore investigated the in vivo relationship between presynaptic striatal dopamine function and 
prefrontal grey matter volume in patients with first episode psychosis. 18F-DOPA PET was used to 
assess dopamine synthesis capacity in the striatum, and voxel-based morphometry was employed to 
evaluate grey matter volume. Consistent with the preclinical findings, we hypothesised that there 
would be an inverse correlation between grey matter volume in the PFC and striatal dopamine 
synthesis capacity in treatment responsive patients, who are hypothesised to have a dopaminergic 
disorder.8 In contrast, we predicted that treatment non-responders would not show a relationship 
between striatal dopamine function and prefrontal volume on the basis of the hypothesis that they do 
not show a dopaminergic disorder and prior findings that non-responders do not show elevated 
dopamine synthesis capacity.7, 36, 37 We further tested our findings in an independent replication 
sample of treatment responders and non-responders.   
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METHODS AND MATERIALS 
Participants 
Discovery sample 
The study was approved by the East of England-Cambridge East NHS Research Ethics Committee. 
We studied 16 patients who had presented to specialised mental health services for first episode 
psychosis in London. Inclusion criteria were: diagnosis of a psychotic disorder according to ICD 10 
criteria38; and within 5 years of the first onset of illness39. All participants provided informed written 
consent to participate. 
Exclusion criteria were: history of significant head trauma, history of neurological disorder, pregnancy 
or breast-feeding, history of alcohol or any other substance abuse or dependence, any significant 
medical disorder, use of antipsychotic drugs for longer than two weeks at baseline.40 
All patients were assessed at baseline, when they received a clinical assessment and PET and MRI scan. 
The clinical assessment was repeated after they had received at least 4 weeks of antipsychotic 
treatment at a therapeutic dose to determine clinical response. This period of minimum 4 weeks did 
not include the time to titrate the antipsychotic to the therapeutic dose. This is in keeping with 
inclusion criteria for a recent large randomised controlled trial of antipsychotic response in first 
episode schizophrenia.41 All patients then received clinical follow-up for at least six months to 
determine if non-responders showed a subsequent response with a longer duration of treatment. The 
choice of antipsychotic was made by the patient in discussion with their treating clinician in line with 
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standard clinical practice. All doses were within the therapeutic range defined in the Maudsley 
Prescribing Guidelines,42 and measures of concordance used (antipsychotic blood monitoring, self-
report and pharmacy records).43 Chlorpromazine-equivalent dose-years44 was calculated to measure 
antipsychotic exposure (see Supplementary Table 1). Use of other psychotropic medication (such as 
antidepressants and benzodiazepines) was permitted. 
The definitions of response and non-response used the Positive and Negative Syndrome Scale (PANSS), 
which was rated at both time-points (ratings were conducted blind to the PET imaging data). We 
defined treatment response as a total PANSS reduction of ш50%.45 Percentage change was adjusted for 
minimum scores (% change in total PANSS = {[(baseline score - 30) - (follow up score - 30)] * 
100}/(baseline score - 30))45 All the subjects received follow-up for six months to determine 
subsequent response in patients. Moreover, treatment response was confirmed using two additional 
criteria. The first approach was based on the administration of the Clinical Global Impression 
Improvement scale (CGI-I).46 A rating of 1 or 2 on the CGI-I (corresponding respectively to “very much 
improved” and “much improved”) equates to a clinically significant improvement.47, 48 Based on this, 
we defined a treatment response as a CGI-I score of 1 or 2, and non-response as a rating of ш3. The 
other one was based on the remission criteria evaluated at 6 months.49 
 
Replication sample 
The study was approved by the institutional review board of Seoul National University Hospital, Seoul, 
Korea, and was carried out in accordance with the Helsinki Declaration of 1975, as revised in 2008. An 
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independent replication sample of patients with schizophrenia was recruited from the Seoul National 
University Hospital: 12 responders (patients whose illness had responded to first-line antipsychotic 
drugs) and 12 non-responders (patients on clozapine who had a history of non-response to at least two 
different first-line antipsychotics but who had shown a response to clozapine, defined as a total score 
of ч80 in the PANSS and no items with a score > 3 on the positive subscale of the PANSS, as reported 
for this sample before).37 Written informed consent was obtained from all subjects. Inclusion criteria: 
diagnosis of schizophrenia according to DSM-IV criteria50 and having been on a stable dose of a first-
line antipsychotic drug including risperidone, olanzapine and paliperidone (responders group) or 
clozapine (non-responders group) for at least 12 weeks. Exclusion criteria were: presence of other 
DSM-IV axis I disorders (including affective episodes), history of alcohol or any other substance 
dependence or abuse, history of significant head trauma, history of neurological disorder, pregnancy or 
breast-feeding, any significant medical disorder. Clinical measures were assessed using the PANSS and 
Clinical Global Impression Severity scale (CGI-S).46 To be classified as treatment responders, patients 
were required to have a CGI-S score of ч 3, a total score of ч 80 in the PANSS and no items with a score 
> 3 on the positive subscale of the PANSS, to have not experienced a symptomatic relapse in the 6 
months prior to the study, and not to have history of being given clozapine or being resistant to first-
line antipsychotic drug treatments.37 
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MRI scanning 
 
Image acquisition 
Discovery sample: Images were acquired on a 3.0 Tesla Signa (GE) system at the Centre for 
Neuroimaging Sciences, IoPPN, London. 196 high-resolution T1-weighted images were acquired using a 
three-dimensional enhanced fast gradient echo sequence using the following scan parameters: 
repetition time – 6.98 msec, echo time – 2.85 msec, flip angle - 11°, matrix – 256 x 256, FoV – 260, slice 
thickness - 1.2 mm. 
Replication sample: Images were acquired on a 3.0 Tesla Siemens Trio MRI scanner. 208 high-
resolution T1-weighted images were acquired using a three-dimensional enhanced fast gradient echo 
sequence using the following scan parameters: repetition time – 1.67 msec, echo time – 1.89 msec, flip 
angle - 9°, matrix – 256 x 256, FoV – 250, slice thickness – 1.0 mm. 
Analysis of MRI data 
Voxel Brain Morphometry Analysis (VBM) of the MRI data was performed using the standard 
Diffeomorphic Anatomical Registration Through Exponentiated Lie Algebra (DARTEL)51 processing 
pipeline in Statistical Parametric Mapping (SPM12; Wellcome Trust Centre for Neuroimaging, London, 
UK, http://www.fil.ion.ucl.ac.uk/spm) via Matlab 8.2 (Mathworks, Natick, MA, USA). The same pipeline 
was used on both discovery and replication sample. Prior to data processing, all the scans were 
checked for artefacts and poor image quality.  Subsequently, each image was reoriented in order to set 
the anterior commissure at the origin of the Montreal Neurological Institute (MNI) coordinate system.  
Following this, the T1-weighted scans were partitioned into different tissue classes - grey matter (GM), 
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white matter (WM) and non-brain voxels (cerebrospinal fluid, skull) based on separate tissue 
probability maps for each tissue class using the segmentation approach implemented in SPM12. The 
DARTEL algorithm was used to generate a study-specific template and the resulting flow fields 
generated by DARTEL were used to obtain GM images of each subject; these images were spatially 
normalised in the MNI space, modulated, resliced (1.5 mm isotropic voxels) and smoothed with a 10-
mm full width at half maximum (FWHM). Total intra-cranial volumes (TIV) were computed using the 
new “Tissue Volumes” utility implemented in SPM12.52 
 
PET scanning 
Image acquisition 
Discovery sample: Dynamic scans were acquired using a Siemens Biograph™ 6 HiRez PET/CT scanner 
(Siemens Medical Systems, Germany) in three-dimensional mode (transaxial resolution of ~5 mm full 
width at half maximum.53 All subjects received 400 mg entacapone, a peripheral catechol-o-methyl-
transferase inhibitor, and 150 mg carbidopa, a peripheral aromatic acid decarboxylase inhibitor, to 
increase specific signal, as these compounds decrease the formation of radiolabelled metabolites that 
may cross the blood–brain barrier.54, 55 Participants were positioned with the orbitomeatal line parallel 
to the transaxial plane of the tomograph. Head position was marked and monitored and movement 
was minimised using a head strap. After a CT scan for attenuation correction and scatter correction, 
approximately 150 MBq of 18F-DOPA was administered by intravenous injection following a 30-s 
background frame. PET data were acquired in 32 frames of increasing duration over the 95 min scan 
(frame intervals: 8x15 seconds, 3x60 seconds, 5x120 seconds, 16x300 seconds). The PET imaging data 
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acquired in a list mode were reconstructed using DIFT (discrete inverse Fourier transform) and a 5mm 
isotropic Gaussian smoothing. The resulting image consisted in 82 axial slices, an image size of 128 x 
128 and a voxel size of 2.0509 x 2.0509 x 2 mm.  
Replication sample: Participants underwent a short CT for attenuation correction and PET imaging on a 
Siemens Biograph 40 Truepoint PET/CT scanner (Siemens, Knoxville, Tennessee, USA) for 95 minutes 
after an intravenous bolus injection of approximately 370 MBq of 18F-DOPA (transaxial resolution of  
~4.2 mm full width at half maximum).37 All the subjects were instructed to take their antipsychotic 
medication at 9 PM a day before the scan, which was performed approximately 17 hours later. They 
received 150 mg carbidopa and 400 mg entacapone orally 1 hour prior to scanning to reduce the 
formation of radiolabeled metabolites. Images were collected in a three-dimensional mode with 148 
axial slices, an image size of 256 x 256 and a voxel size of 1.3364 x 1.3364 x 3 mm. The dynamic 
volumetric images were reconstructed using filter-back projection into 27 frames sequenced using the 
following framing: 2×30 seconds, 4×60 seconds, 3×120 seconds, 3×180 seconds, and 15×300 seconds. 
Analysis of PET data 
In both discovery and replication sample, head movement correction was conducted using a level 2, 
order 64 Battle-Lemarie wavelet filter to denoise non-attenuation-corrected dynamic images. Frames 
were realigned to a single reference frame (characterised with the highest measured PET activity), 
acquired 20 minutes post-injection, employing a mutual information algorithm.56, 57 The 
transformation parameters were then applied to the corresponding attenuated-corrected dynamic 
images, creating a movement-corrected dynamic image, which was used in the analysis. Realigned 
frames were then summated to create an individual motion-corrected reference map for the brain 
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tissue segmentation.  SPM8 (http://www.fil.ion.ucl.ac.uk/spm) was used to normalize a tracer-specific 
(18F-DOPA) template33, 58 together with the striatal probabilistic brain atlas59 to each individual PET 
summation image. Importantly, the PET pre-processing was not based on the MRI images; thus, the 
correlations between PET and MRI data were independent of co-registration. An eroded cerebellar 
region was used as reference for tissue quantification in agreement with previous analyses.60 Tracing 
and tractography studies have shown that the cortical projections to the striatum show a 
topographical distribution across the striatum.61-63 Projections from limbic regions such as the 
hippocampus project to anterior and ventral regions of the striatum, projections from regions involved 
in associative cognitive functions such as the dorsolateral prefrontal cortex (DLPFC) project to the head 
of caudate and anterior putamen, and projections from sensorimotor cortex project to more dorsal 
and posterior regions of the striatum, predominantly putamen. The striatum can thus be sub-divided 
into limbic, associative and sensorimotor sub-divisions respectively based on this topography. We sub-
divided the striatum into these sub-regions as previously described.33, 59 The striatal influx constant 
(Kicer, written as Ki in some previous publications)33 was calculated relative to uptake in the reference 
region using a graphical approach adapted for a reference tissue input function.64 A previous test/re-
test study has shown this approach has good reliability with an intra-class correlation coefficient of 
>0.84 for the whole striatum.58 Further details of the image analysis approach are given in Jauhar et 
al65 and Bloomfield et al.60 The PET, but not MR, data have been reported for the discovery sample in 
Jauhar et al7, 66 and for the replication sample in Kim et al.37 
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Integration of MRI and PET data - statistical analyses 
A general linear model in SPM12 was used to test the negative interaction between treatment 
response, whole striatum dopamine synthesis capacity (entered in the statistical model as Kicer value) 
and grey matter volume. The analysis was masked using the WFU Pick-Atlas67 with an ROI in the DLPFC 
identified as lateral BA9 and BA 4668, 69 because of our a priori hypothesis based on the fact this brain 
region has been consistently implicated in the pathophysiology of schizophrenia70, 71 and sends a large 
number of cortico-striatal projections63, 72. Results were initially visualised at the statistical threshold of 
p< 0.001 uncorrected with a minimal cluster size (k) of 50 contiguous voxels and then corrected for 
multiple comparisons at the voxel level (FWE correction). The software MRIcroGL 
(http://www.mccauslandcenter.sc.edu/mricrogl/) was used for the visualisation of the results. For 
descriptive purposes, grey matter volume values were extracted from the significant clusters using the 
MarsBar 0.44 SPM toolbox (http://marsbar.sourceforge.net/) and plotted against Kicer values using 
GraphPad Prism 7.02 (http://www.graphpad.com/). The analysis in the replication sample was 
performed using the same procedure. 
The grey matter volume values extracted from the significant clusters in DLPFC were compared 
between responders and non-responders. Moreover, whole brain VBM analyses were performed in 
each sample to test for any GM volumetric differences between responders and non-responders. 
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Separate exploratory analyses in the discovery and replication samples were conducted using 
associative striatum, limbic striatum and sensorimotor striatum Kicer as predictors. Moreover, to test 
the specificity of the findings, we performed exploratory ROI analyses, examining the correlation 
between dopamine synthesis capacity in the limbic and sensorimotor striatal subdivisions and GM 
volume of the corresponding frontal regions.35 Specifically, we used a ROI in the limbic areas of the 
frontal cortex, which included medial prefrontal cortex and orbitofrontal cortex, for the limbic striatum 
Kicer analysis; and a ROI in primary and supplementary motor cortex for the sensorimotor striatum Kicer 
analysis.73, 74 The correlation between associative striatum Kicer and DLPFC (the corresponding cortical 
region)63 was not repeated, as it was already included in the above analyses. 
A further confirmation of the specificity of the finding was obtained by performing ROIs analyses with 
Kicer as predictors and ROIs in all the brain areas other than PFC (ROIs selected by using the WFU Pick-
Atlas).67 
All the statistical models above included age, gender and total intra-cranial volume (TIV) as “nuisance” 
variables, in order to control for any independent effects on our findings and to ensure that the 
analysis identified regionally specific “non-global” effects.75, 76 
For illustrative purposes, we computed effect sizes from the maximum T statistic obtained from the 
significant clusters77 and meta-analysed them using Comprehensive Meta-Analysis Version 3.78 
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RESULTS 
Demographic (± SD) and Kicer values of the samples included in the experiments are reported in Table 1 
and Supplementary Table 1. 
Discovery sample 
All the subjects defined as responders according to the PANSS criterion had a CGI-I score of 1 or 2 
(mean= 1.3). All the non-responders (as for the PANSS criterion) had a CGI-I score of ш3 (mean= 4.1). At 
six-month follow up there were no changes in terms of treatment response status. We found an 
interaction between treatment response, whole striatal dopamine synthesis capacity and grey matter 
volume in left (BA 9: x= -40, y= 36, z= 38; k= 158, Z= 4.22, pFWE corrected= 0.017) and right (BA 9: x= 
32, y= 54, z= 33; k= 163, Z= 3.94, pFWE corrected= 0.042) prefrontal cortex [Table 2]. Figure 1 
illustrates that treatment responders show a negative correlation between prefrontal grey matter and 
striatal dopamine synthesis capacity but this is not present in treatment non-responders. 
Responders and non-responders did not differ in terms of grey matter volume values extracted from 
the significant clusters. Moreover, the VBM whole brain analysis did not show any significant 
differences in terms of grey matter volume between the two groups (no clusters surviving FWE 
correction). 
Replication sample 
None of the responders had a score of 4 or more on any item of the PANSS positive subscale. All the 
patients had been clinically stable for longer than 6 months (responders: 37.9 ± 20.4 months; non-
responders: 40.2 ± 19.9 months). There was an interaction between treatment response to first-line 
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antipsychotics, whole striatal dopamine synthesis capacity and grey matter volume in right prefrontal 
cortex (BA 9: x= 20, y= 46, z= 38; k= 57, Z= 3.93, pFWE corrected= 0.031) [Table 3]. Patients who 
responded to first-line antipsychotics showed a negative correlation between prefrontal grey matter 
and striatal dopamine synthesis capacity. In non-responders no relationship was present [Figure 2]. 
Also in this sample there were no differences in terms of grey matter volume in the DLPFC or at a 
whole brain level. 
The summary (discovery + replication samples) effect size for the interaction between treatment 
response, whole striatal dopamine synthesis capacity and prefrontal grey matter volume was 0.82 
(calculated using Hedges’ g approach). 
 
Exploratory analyses: correlations with Kicer in the different striatal subdivisions in the discovery 
sample 
We found an interaction between treatment response, Kicer value in the associative striatum and grey 
matter volume in left (BA 9: x= -42, y= 34, z= 38; k= 166, Z= 4.30, pFWE corrected= 0.013) and right (BA 
9: x= 32, y= 54, z= 34; k= 138, Z= 3.92, pFWE corrected= 0.046) prefrontal cortex [Supplementary Table 
2] [Supplementary Figure 1]. The exploratory analysis with the sensorimotor subdivision Kicer as 
predictor revealed that only the cluster in right prefrontal cortex survived FWE correction (BA 9: x= 34, 
y= 50, z= 34; k= 190, Z= 3.93, pFWE corrected= 0.043) [Supplementary Table 2] [Supplementary Figure 
2]. The results from the exploratory analysis with the limbic subdivision Kicer as predictor did not 
survive FWE correction. 
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Exploratory analysis with limbic striatal Kicer as predictor and ROI in the limbic area of frontal cortex did 
not show significant clusters. 
Exploratory analysis with sensorimotor Kicer as predictor and ROI in the primary and supplementary 
cortex did not show any significant clusters. All the ROI exploratory analyses with dopamine synthesis 
capacity as predictor and ROIs in all the brain areas other than PFC did not show voxels surviving FWE 
correction. 
Exploratory analyses: correlations with Kicer in the different striatal subdivisions in the replication 
sample 
We found an interaction between treatment response, Kicer value in the sensorimotor striatum and 
grey matter volume in right prefrontal cortex (BA 9: x= 18, y= 48, z= 38; k= 46, Z= 3.89, pFWE 
corrected= 0.034) [Supplementary Table 2] [Supplementary Figure 3]. The results from the exploratory 
analyses with the limbic and associative subdivisions Kicer as predictors did not survive FWE correction. 
DISCUSSION 
Our main finding is an inverse correlation between grey matter volume in the DLPFC and dopamine 
synthesis capacity in the whole striatum in patients with psychosis who respond to treatment, but no 
relationship in patients who do not respond to first-line treatment. Specifically, in patients who had 
responded to first-line antipsychotics, lower prefrontal grey matter volume was associated with 
increased dopamine synthesis capacity in the whole striatum. We replicated this finding in an 
independent sample of patients with chronic schizophrenia. 
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As predicted, the two subgroups of patients (responders and non-responders) showed differences in  
correlations between the measures examined. These results lend further evidence to the theory that 
the neurobiology underlying treatment-resistant psychosis is different from that seen in treatment-
responsive schizophrenia.8 Moreover, it has been observed that patients who respond to 
antipsychotics have higher striatal density of dopaminergic synapses79 and higher striatal dopamine 
synthesis capacity7, 36, 37 when compared with patients with treatment-resistant illness, whilst the latter 
show greater frontal cortical glutamate levels.80, 81 This has led to speculation that only those patients 
whose illness is characterized by dopaminergic dysfunction will show a good response to dopamine-
blocking antipsychotics.8 
The results of this study are consistent with previous findings of a correlation between measures of 
neuronal integrity and evoked release of striatal dopamine in patients with schizophrenia29 and 
between prefrontal cortex functional activation and dopamine synthesis capacity in subjects with an 
at-risk mental state and patients with schizophrenia.28, 82, 83 They are also consistent with evidence of 
direct and indirect anatomical connections between PFC and striatum84, 85 and with the pre-clinical 
lesions studies and the long-standing hypothesis of dysregulation of the striatal dopaminergic system 
being secondary to prefrontal cortex pathology in schizophrenia,21-24 but critically also extend the 
hypothesis to indicate it can be applied to treatment-responsive schizophrenia only.  This is in line with 
recent evidence of a relationship between treatment response and cortico-striatal connectivity in 
schizophrenia.86 
Projections from the prefrontal cortex act as a “brake” on the striatal dopaminergic system.87, 88 Thus, if 
lower PFC volume reflects fewer or disrupted inhibitory projections from the PFC, then this could lead 
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to a relative disinhibition of striatal dopamine function, which would explain the negative relationship 
we observed in the treatment responders. However, further work is required to test whether lower 
PFC volume is associated with disrupted projections. 
Although there have been prior investigations of the relationship between dopaminergic function and 
cerebral morphology in healthy volunteers,25, 26, 89-92 to the best of our knowledge this is the first study 
investigating this relationship in patients with psychosis. 
The exploratory analyses performed in the discovery sample with the different striatal subdivisions 
showed statistically significant relationships between bilateral prefrontal cortex and dopamine 
synthesis capacity in the associative striatum subdivision. This is consistent with the evidence that the 
associative subdivision of the striatum receives a large number of inputs from the DLPFC,61, 93-96 and 
extends previous studies that have localized dopaminergic dysfunction in schizophrenia to associative 
regions of the striatum,33-35 to indicate that striatal dopaminergic dysfunction is linked to structural 
alterations in the disorder. However, the specificity of the involvement of the associative striatum was 
not confirmed by the exploratory analyses in the replication sample. Differences in segmentation or 
normalisation can lead to variations in the analyses of small areas such as the striatal subdivisions; 
therefore, further studies are needed to explore the involvement of the specific loci within the 
striatum. 
We did not find any statistically significant differences in grey matter volumes between responders and 
non-responders. This may reflect the fact that the present study was not powered to detect grey 
matter volume differences, which are expected to be small in terms of effect size.97 
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It is important to consider that treatment-resistant psychosis may be characterized by greater 
heterogeneity;98 thus, non-responders might have more variability in imaging measures leading to 
overall non-significant correlations. However, it should be noted that the findings were replicated in a 
sample of non-responders to first-line antipsychotics but homogeneous in terms of response to 
clozapine and, therefore, likely to be neurobiologically similar.99-101 Nevertheless, given heterogeneity 
in structural volumes in schizophrenia,10 further work would be useful to exclude variability as an 
explanation of our findings. 
Interpretation and Limitations 
Grey matter volume reflects a number of aspects of tissue composition, including the number of 
projection neurons and interneurons, and synaptic density.102, 103 Thus, further work is required to 
determine if it is lower density of projection neurons to the striatum that underlies the association we 
see. It should also be noted that we used an ROI approach and that the family-wise error correction 
that we applied is relatively conservative and thus there may be a risk of a type II error for other 
regions that could be linked to striatal dopaminergic dysfunction.104 Nevertheless, the application of 
family-wise error correction gives confidence in the association between prefrontal cortex and 
associative striatal dopaminergic function. 
However, it is important to recognise that association does not necessarily imply causality, and it 
should be recognised that some preclinical models also indicate that selective increases in striatal 
dopaminergic neurotransmission can affect frontal cortical function.105 Moreover, elevated striatal 
dopamine synthesis and release capacity has been reported in people at risk of psychosis,31, 32, 106 and 
to increase during the prodrome,107 whilst frontal volume has been found to reduce during the 
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prodrome.108-110 Longitudinal multimodal studies and pre-clinical studies are necessary to clarify the 
timing of these alterations and determine which is primary. An example of such a preclinical studies is 
that one conducted in mice by Kim et al111 where it has been shown that cortical spine density 
influences striatal dopamine release via monosynaptic control of dopaminergic neurons; specifically 
spine loss in prefrontal cortex led to increased striatal dopamine release and hyperactivity which was 
normalised by haloperidol. 
Two recent studies have examined the relationship between striatal dopamine release and frontal 
cortical thickness in healthy controls.25, 26 We would hypothesise a similar negative relationship 
between prefrontal cortical volume and striatal dopaminergic function in healthy volunteers, in 
keeping with our findings in people with psychosis who have good clinical response. It would be useful 
to test this in a further study. 
Previous studies have demonstrated a correlation between glutamatergic neurometabolites and 
cerebral structural measures in schizophrenia.112, 113 It would be interesting to explore if this 
relationship is different in treatment responders and non-responders, especially in the context of the 
putative role of the glutamatergic system in the neurobiology of treatment-resistant schizophrenia.80, 
81 
Understanding the underlying neurobiology of schizophrenia is essential for the rationale development 
of new treatments. Our study provides further evidence that schizophrenia should be recognised as a 
condition with at least two neurobiologically different subtypes. 
A potential limitation is that some clinical and demographic variables differ between the discovery and 
replication samples. Specifically, the duration of antipsychotic treatment and duration of illness differ, 
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and either may have effects on GM volume114-116 and, potentially, on dopamine synthesis capacity.117, 
118 Despite this, effects were seen separately in each sample, suggesting the relationship between 
prefrontal cortical volume and striatal dopamine synthesis capacity in responders is a trait factor 
underlying the neurobiology of psychosis. 
The subjects in the replication sample received a higher dose of 18F-DOPA. However, the administered 
dose in both samples are within the standard range used in imaging studies.33, 65, 119-122 Doses within 
the standard imaging range are not thought to lead to appreciable differences in signal to noise 
ratio.123 Moreover, because of the quantification approach, the activity in the striatum (target region) 
is normalised to the one in the cerebellum (reference region). For this reason, differences in the 
injected dose are not expected to influence the Kicer values. 
Whilst the Kicer values appear higher in the replication sample relative to the discovery sample, this 
could be due to scanner and other methodological differences.106 
The summary effect size was large. However, it should be considered that traditional neuroimaging 
studies are not optimized to estimate effect sizes and post hoc effect sizes calculated from imaging 
studies can be inflated.124 
Even though the findings were replicated in an independent sample, we should consider the relatively 
low sample size as a limitation. Therefore, future studies in larger samples are needed. 
The discovery sample was in subjects with a diagnosis of first episode psychosis. It is important to 
recognise that first episode samples generally include patients who subsequently receive a diagnosis of 
bipolar affective disorder as well as schizophrenia. Indeed diagnoses often change in the first few years 
of a psychotic illness.125 In view of this, it is important to appreciate that the findings in the discovery 
sample may not be specific to schizophrenia. However, in the replication sample we had a sample with 
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an established diagnosis of schizophrenia. As the replication sample confirmed the findings in the 
discovery sample, this indicates that the findings are relevant for schizophrenia but, as we did not have 
a replication sample with bipolar or other psychotic disorders, we cannot comment on the specificity of 
our findings in the discovery sample to schizophrenia or psychotic disorders in general. In view of 
recent evidence that striatal dopaminergic dysfunction also underlies psychosis in bipolar disorder,66 
future studies investigating this would be useful. 
Another potential limitation is that in the discovery sample there was a difference in medication status 
between responders and non-responders. However, the findings were replicated in a sample 
homogeneous in terms of medication status. Moreover, dopamine synthesis capacity has been recently 
demonstrated to be unaltered by second-generation antipsychotic treatment at doses commonly used 
in first episode patients,118 although it may be altered by following treatment with first-generation 
antipsychotic.117 
 
Conclusions 
 
To our knowledge, the present study is the first to test the relationship between frontal cortical 
volume and striatal dopamine function in patients, finding in vivo evidence for an inverse correlation 
between prefrontal grey matter volume and striatal dopamine synthesis capacity in patients with 
psychosis. Moreover, the fact that treatment-resistant patients do not show this correlation suggests 
that different mechanisms underlie the pathophysiology of treatment-responsive and treatment-
resistant psychosis. Future studies are needed to clarify the pathoetiology responsible for these two 
potentially neurobiologically different forms of psychotic disorder. 
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FIGURE LEGENDS 
 
Figure 1 
Interaction GM volume in PFC x whole striatum Kicer x treatment response (discovery sample) 
Colour bar represents T score values. 
 
Figure 2 
Interaction GM volume in PFC x whole striatum Kicer x treatment response (replication sample) 
Colour bar represents T score values. 
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TABLE LEGENDS 
 
Table 1 
Demographic characteristics of the sample 
Medication status classification: antipsychotic naïve, antipsychotic free (prior oral antipsychotic 
medication but free of treatment for at least 6 weeks (oral) or 6 months (depot, if relevant)) or 
minimally treated (taking antipsychotic medication for two weeks or less). 
 
Table 2 
Interaction GM volume in PFC x striatal Kicer x treatment response (discovery sample) 
 
Table 3 
Interaction GM volume in PFC x striatal Kicer x treatment response (replication sample) 
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 1
Table 2 
Interaction GM volume in PFC x striatal Kicer x treatment response (discovery sample) 

Correlation with MNI coordinates Subregion BA cluster size (k)  Z pFWE 
corr. 
whole striatum 
Kicer 
 
-40 36 38 Left Sup Frontal 
Gyrus 
9 158  4.22 0.017* 
32 54 33 Right Sup Frontal 
Gyrus 
9 163  3.94 0.042* 
 
 1
 
Table 3 
Interaction GM volume in PFC x striatal Kicer x treatment response (replication sample) 
 
Correlation with  MNI coordinates Subregion BA cluster size (k)  Z p FWE corr.  
whole striatum 
Kicer 
20 46 38 Right Sup Frontal 
Gyrus 
9 57  3.93 0.031* 
 
 
 
 
 
SUPPLEMENTARY INFORMATION 
 
 
Supplementary Table 1 
Psychotropic medication 
 
Supplementary Table 2 
Exploratory analyses - Interaction GM volume in PFC x Kicer (striatal subdivisions) x treatment 
response 
 
Supplementary Figure 1 
Exploratory analysis - Interaction GM volume in PFC x associative striatum Kicer x treatment 
response (discovery sample) 
Colour bar represents T score values. 
 
Supplementary Figure 2 
Exploratory analysis - Interaction GM volume in PFC x sensorimotor striatum Kicer x treatment 
response (discovery sample) 
Colour bar represents T score values. 
 
Supplementary Figure 3 
Exploratory analysis - Interaction GM volume in PFC x sensorimotor striatum Kicer x treatment 
response (replication sample) 
Colour bar represents T score values. 
 
 
Supplementary Table 1 
Psychotropic medication 
 Analysis in the discovery sample 
 Responders Non-
responders 
p-value 
Chlorpromazine 
equivalents (dose 
years) between 
scan and follow-
up clinical 
assessment 
(mean ± SD) 
0.40 ± 0.31 0.43 ± 0.28 0.85 


 Analysis in the replication sample 
 Responders 
(first-line AP 
group) 
Non-responders 
(clozapine group) 
p-value 
Chlorpromazine 
equivalents 
(mg/day) (mean 
± SD) 
285.4 ± 153.2 261.4 ± 117.5 0.67 
Duration of 
exposure to 
current 
antipsychotics 
(months) (mean 
± SD) 
64.1 ± 18.2 76.3 ± 12.4 0.58 

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